Azacitidine Mylan 25 mg/mL powder for suspension for injection

DRUG3 trials

Sponsors

Takeda Development Center Americas Inc., Centre Hospitalier De Versailles, Centre Hospitalier Universitaire De Toulouse

Conditions

Acute Myeloid LeukemiaRelapsed/refractory T-cell Acute Lymphoblastic Leukemia

Phase 2

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

CompletedCTIS2024-515424-36-00

Takeda Development Center Americas Inc.Acute Myeloid Leukemia

Start: 2020-10-15End: 2025-10-06Target: 2Updated: 2025-06-24

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

Not yet recruitingCTIS2024-516570-30-00

Centre Hospitalier De VersaillesRelapsed/refractory T-cell Acute Lymphoblastic Leukemia

Target: 12Updated: 2026-05-29

Phase 3

Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2

Not yet recruitingCTIS2026-525759-96-00

Centre Hospitalier Universitaire De ToulouseAcute Myeloid Leukemia

Target: 1290Updated: 2026-10-23